Literature DB >> 9665915

Study is needed of visual field defects associated with any long term antiepileptic drug.

G P Rao, F A Fat, G Kyle, J P Leach, D W Chadwick, M Batterbury.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1998        PMID： 9665915      PMCID： PMC1113550          DOI： 10.1136/bmj.317.7152.206

Source DB:  PubMed          Journal:  BMJ        ISSN： 0959-8138


× No keyword cloud information.
  3 in total

1.  Severe persistent visual field constriction associated with vigabatrin. Benefit: risk ratio must be calculated for individual patients.

Authors:  G F Harding
Journal:  BMJ       Date:  1998-01-17

2.  Severe persistent visual field constriction associated with vigabatrin. Asymptomatic as well as symptomatic defects occur with vigabatrin.

Authors:  R Mackenzie; A Klistorner
Journal:  BMJ       Date:  1998-01-17

3.  Severe persistent visual field constriction associated with vigabatrin.

Authors:  T Eke; J F Talbot; M C Lawden
Journal:  BMJ       Date:  1997-01-18
  3 in total
  6 in total

1.  Visual field defect associated with vigabatrin. Many more patients may be affected than were found in study.

Authors:  I F Comaish; C Gorman; N R Galloway
Journal:  BMJ       Date:  2000-05-20

2.  Long term changes in the visual fields of patients with temporal lobe epilepsy using vigabatrin.

Authors:  P Hardus; W M Verduin; G Postma; J S Stilma; T T Berendschot; C W van Veelen
Journal:  Br J Ophthalmol       Date:  2000-07       Impact factor: 4.638

3.  Visual field constriction and electrophysiological changes associated with vigabatrin.

Authors:  Dorothea Besch; Anne Kurtenbach; Eckart Apfelstedt-Sylla; Bettina Sadowski; Dieter Dennig; Christiane Asenbauer; Eberhart Zrenner; Ulrich Schiefer
Journal:  Doc Ophthalmol       Date:  2002-03       Impact factor: 2.379

4.  Visual field defects associated with vigabatrin therapy.

Authors:  M C Lawden; T Eke; C Degg; G F Harding; J M Wild
Journal:  J Neurol Neurosurg Psychiatry       Date:  1999-12       Impact factor: 10.154

5.  Modelling the topography of absolute defects in patients exposed to the anti-epileptic drug vigabatrin and in normal subjects using automated static suprathreshold perimetry of the entire 80° visual field.

Authors:  Dorothea Besch; Ulrich Schiefer; Nicole Eter; Roland Burth; Christian E Elger; Manfred Spitznas; Klaus Dietz
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2011-03-05       Impact factor: 3.117

Review 6.  Visual field defects and other ophthalmological disturbances associated with vigabatrin.

Authors:  S J Spence; R Sankar
Journal:  Drug Saf       Date:  2001       Impact factor: 5.228
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.